Bristol Myers Squibb (BMS) is set to invest a substantial $40 billion in the United States over the coming five years. This investment aims to expand the company's research, development, and manufacturing footprint across the country, particularly as the pharmaceutical industry faces potential import tariffs proposed by President Donald Trump. Reuters reported that this approach is intended to fortify BMS's U.S. presence amidst these pending policy changes.
A key aspect of BMS's investment is to enhance its manufacturing capabilities within the United States. This move is designed to secure greater control over complex supply chains by aligning production closely with its research facilities. The significant financial commitment also earmarks funds for technological advancements, including radiopharmaceutical manufacturing and the integration of artificial intelligence and machine learning, which are intended to catalyze the company's innovative capacities.
The investment strategy by BMS coincides with industry-wide preparations for possible tariffs, as reported by Reuters. Additionally, it follows the Trump administration's streamlined efforts to hasten pharmaceutical plant approvals, supporting domestic manufacturing initiatives. Last year, BMS expanded its investment in radiopharmaceuticals by acquiring RayzeBio for $4.1 billion, which bolsters its cancer treatment pipeline.